Compounds > dehydrodiconiferyl alcohol
Page last updated: 2024-12-11

dehydrodiconiferyl alcohol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dehydrodiconiferyl alcohol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dehydrodiconiferyl alcohol : A guaiacyl lignin obtained by cyclodimerisation of coniferol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5372367
CHEMBL ID4163889
CHEBI ID91184
SCHEMBL ID12963315
MeSH IDM0215488

Synonyms (32)

Synonym
MEGXP0_000971
dehydrodiconiferyl alcohol
97465-82-2
4-[3-(hydroxymethyl)-5-[(e)-3-hydroxyprop-1-enyl]-7-methoxy-2,3-dihydro-1-benzofuran-2-yl]-2-methoxyphenol
4263-87-0
3-benzofuranmethanol, 2,3-dihydro-2-(4-hydroxy-3-methoxyphenyl)-5-(3-hydroxy-1-propenyl)-7-methoxy-
bdbm50340634
chembl4163889 ,
KUSXBOZNRPQEON-ONEGZZNKSA-N
4-(3-(hydroxymethyl)-5-[(1e)-3-hydroxy-1-propenyl]-7-methoxy-2,3-dihydro-1-benzofuran-2-yl)-2-methoxyphenol #
diconiferyl alcohol, dehydro-
coniferyl alcohol, dehydrodi-
3-benzofuranmethanol, 2,3-dihydro-2-(4-hydroxy-3-methoxyphenyl)-5-(3-hydroxypropenyl)-7-methoxy-
SCHEMBL12963315
g(8-5)g
CHEBI:91184
4-{3-(hydroxymethyl)-5-[(1e)-3-hydroxyprop-1-en-1-yl]-7-methoxy-2,3-dihydro-1-benzofuran-2-yl}-2-methoxyphenol
dehydrodiconiferol
lignin cw compound-2004
dehydrodiconiferylalkohol
4-(3-(hydroxymethyl)-5-(3-hydroxyprop-1-en-1-yl)-7-methoxy-2,3-dihydrobenzofuran-2-yl)-2-methoxyphenol
Q27105134
(e)-4-(3-(hydroxymethyl)-5-(3-hydroxyprop-1-en-1-yl)-7-methoxy-2,3-dihydrobenzofuran-2-yl)-2-methoxyphenol
528814-97-3
AS-79327
E88878
(e)-dehydrodiconiferyl alcohol
3-benzofuranmethanol,2,3-dihydro-2-(4-hydroxy-3-methoxyphenyl)-5-[(1e)-3-hydroxy-1-propenyl]-7-methoxy-, (2s,3r)-
AKOS040761592
AKOS040758179
CS-0202728
HY-N2682B
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
1-benzofuransA member of the class of benzofurans consisting of a 1-benzofuran skeleton and its substituted derivatives thereof.
primary alcoholA primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.
guaiacyl ligninLignin composed principally of coniferol (guaiacyl) units.
guaiacolsAny phenol carrying an additional methoxy substituent at the ortho-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptorHomo sapiens (human)IC50 (µMol)0.06190.00000.723732.7000AID1355268
Estrogen receptor betaHomo sapiens (human)IC50 (µMol)0.28650.00010.529432.7000AID1355269
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (44)

Processvia Protein(s)Taxonomy
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
signal transductionEstrogen receptor betaHomo sapiens (human)
cell-cell signalingEstrogen receptor betaHomo sapiens (human)
negative regulation of cell growthEstrogen receptor betaHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptor betaHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptor betaHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptor betaHomo sapiens (human)
DNA bindingEstrogen receptor betaHomo sapiens (human)
nuclear steroid receptor activityEstrogen receptor betaHomo sapiens (human)
nuclear receptor activityEstrogen receptor betaHomo sapiens (human)
steroid bindingEstrogen receptor betaHomo sapiens (human)
protein bindingEstrogen receptor betaHomo sapiens (human)
zinc ion bindingEstrogen receptor betaHomo sapiens (human)
enzyme bindingEstrogen receptor betaHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptor betaHomo sapiens (human)
estrogen response element bindingEstrogen receptor betaHomo sapiens (human)
receptor antagonist activityEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
nucleoplasmEstrogen receptor betaHomo sapiens (human)
mitochondrionEstrogen receptor betaHomo sapiens (human)
intracellular membrane-bounded organelleEstrogen receptor betaHomo sapiens (human)
chromatinEstrogen receptor betaHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (80)

Assay IDTitleYearJournalArticle
AID1355251Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as decrease in size of TRAP-positive multinucleated cells at 20 uM after 5 days in presence of ERbeta antagonist PHTPP by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355236Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as TRAP activity after 5 days in presence of CAMKKbeta inhibitor STO6092018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355241Inhibition of RANKL-induced PKA phosphorylation in mouse RAW264.7 cells at 10 to 40 uM after 24 hrs by Western blot analysis2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355252Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as decrease in TRAP activity at 20 uM after 5 days in presence of ERbeta antagonist PHTPP by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355278Anti-osteoporotic activity in Balb/c mouse assessed as decrease in OVX-induced trabecular pattern factor in femur at 25 to 100 mg/kg, ip administered for 4 weeks daily by microcomputed tomography2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355250Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as decrease in number of TRAP-positive multinucleated cells at 20 uM after 5 days in presence of ERbeta antagonist PHTPP by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355280Anti-osteoporotic activity in Balb/c mouse assessed as inhibition of OVX-induced serum NTx level at 25 to 100 mg/kg, ip administered for 4 weeks daily by ELISA2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355213Cytotoxicity against mouse RANKL-treated RAW264.7 cells assessed as reduction in cell viability at 10 to 40 uM after 72 hrs by MTT assay2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355239Induction of estrogen receptor-mediated AMPKalpha1 activation in mouse RAW264.7 cells at 20 uM in presence of PKA inhibitor H892018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355260Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring ERalpha siRNA assessed as decrease in TRAP mRNA level at 20 uM after 24 hrs by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355264Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring ERbeta siRNA assessed as decrease in TRAP activity at 20 uM after 5 days by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355271Anti-osteoporotic activity in ip dosed OVX-induced bone loss in femur of Balb/c mouse administered for 4 weeks daily by microcomputed tomography2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355285Anti-osteoporotic activity in Balb/c mouse assessed as inhibition of OVX-induced c-Fos mRNA expression level in bone marrow at 25 to 100 mg/kg, ip administered for 4 weeks daily by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355282Anti-osteoporotic activity in Balb/c mouse assessed as inhibition of OVX-induced TRAP mRNA expression level in bone marrow at 25 to 100 mg/kg, ip administered for 4 weeks daily by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355210Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as decrease in size of TRAP-positive multinucleated cells after 5 days by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355269Inhibition of fluoromone binding to recombinant human full length untagged ERbeta expressed in insect cells after 2 hrs by fluorescence polarization assay2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355209Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as decrease in number of TRAP-positive multinucleated cells after 5 days by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355219Inhibition of NF-kappaB/p38 MAPK signaling pathway in mouse RAW264.7 cells assessed as reduction in RANKL-induced cathepsin K mRNA level after 24 hrs by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355274Anti-osteoporotic activity in Balb/c mouse assessed as inhibition of OVX-mediated decrease in trabecular number in femur at 25 to 100 mg/kg, ip administered for 4 weeks daily by microcomputed tomography2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355238Induction of estrogen receptor-mediated AMPKalpha1 activation in mouse RAW264.7 cells at 20 uM in presence of estrogen receptor antagonist fulvestrant2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355214Inhibition of NF-kappaB/p38 MAPK signaling pathway in mouse RAW264.7 cells assessed as reduction in RANKL-induced NFATc1 mRNA level after 24 hrs by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355218Inhibition of NF-kappaB/p38 MAPK signaling pathway in mouse RAW264.7 cells assessed as reduction in RANKL-induced DC-STAMP mRNA level after 24 hrs by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355275Anti-osteoporotic activity in Balb/c mouse assessed as inhibition of OVX-mediated decrease in bone marrow density in femur at 25 to 100 mg/kg, ip administered for 4 weeks daily by microcomputed tomography2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355249Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as decrease in NFATc1 mRNA level at 20 uM after 24 hrs in presence of ERalpha antagonist MPP by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355272Anti-osteoporotic activity in Balb/c mouse assessed as inhibition of OVX-mediated decrease in trabecular bone volume in femur at 25 to 100 mg/kg, ip administered for 4 weeks daily by microcomputed tomography2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355208Inhibition of NF-kappaB signaling pathway in mouse RAW264.7 cells assessed as reduction in RANKL-induced IKKbeta phosphorylation at 10 to 40 uM after 30 mins by Western blot method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355231Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring AMPKalpha1 siRNA assessed as decrease in TRAP activity at 10 to 40 uM after 5 days by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355223Inhibition of NF-kappaB signaling pathway in mouse RAW264.7 cells assessed as reduction in RANKL-induced Akt phosphorylation at 10 to 40 uM after 30 mins by Western blot method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355244Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as decrease in number of TRAP-positive multinucleated cells at 20 uM after 5 days in presence of ERalpha antagonist MPP by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355255Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as decrease in NFATc1 mRNA level at 20 uM after 24 hrs in presence of ERbeta antagonist PHTPP by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355224Inhibition of NF-kappaB signaling pathway in mouse RAW264.7 cells assessed as reduction in RANKL-induced IkappaB phosphorylation at 10 to 40 uM after 30 mins by Western blot method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355270Selectivity ratio of IC50 for recombinant human full length untagged ERbeta expressed in insect cells to IC50 for recombinant human full length untagged ERalpha expressed in insect cells2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355276Anti-osteoporotic activity in Balb/c mouse assessed as decrease in OVX-induced trabecular bone surface in femur at 25 to 100 mg/kg, ip administered for 4 weeks daily by microcomputed tomography2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355242Inhibition of RANKL-induced CAMKKbeta phosphorylation in mouse RAW264.7 cells at 10 to 40 uM after 24 hrs by Western blot analysis2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355256Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring ERalpha siRNA assessed as decrease in number of TRAP-positive multinucleated cells at 20 uM after 5 days by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355233Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring AMPKalpha1 siRNA assessed as decrease in NFATc1 mRNA level at 20 uM after 24 hrs by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355265Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring ERbeta siRNA assessed as decrease in c-Fos mRNA level at 20 uM after 24 hrs by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355243Agonist activity at estrogen receptor (unknown origin) expressed in mouse RAW264.7 cells after 6 hrs by luciferase reporter gene assay2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355261Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring ERalpha siRNA assessed as decrease in NFATc1 mRNA level at 20 uM after 24 hrs by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355217Inhibition of NF-kappaB/p38 MAPK signaling pathway in mouse RAW264.7 cells assessed as reduction in RANKL-induced MMP-9 mRNA level after 24 hrs by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355215Inhibition of NF-kappaB/p38 MAPK signaling pathway in mouse RAW264.7 cells assessed as reduction in RANKL-induced c-Fos mRNA level after 24 hrs by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355225Inhibition of p38 MAPK signaling pathway in mouse RAW264.7 cells assessed as reduction in RANKL-induced p38 phosphorylation at 10 to 40 uM after 30 mins by Western blot method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355273Anti-osteoporotic activity in Balb/c mouse assessed as inhibition of OVX-mediated decrease in trabecular thickness in femur at 25 to 100 mg/kg, ip administered for 4 weeks daily by microcomputed tomography2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355263Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring ERbeta siRNA assessed as decrease in size of TRAP-positive multinucleated cells at 20 uM after 5 days by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355284Anti-osteoporotic activity in Balb/c mouse assessed as inhibition of OVX-induced cathepsin K mRNA expression level in bone marrow at 25 to 100 mg/kg, ip administered for 4 weeks daily by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355228Activation of AMPKalpha1 in mouse RAW264.7 cells assessed as increase in AMPK phosphorylation at 10 to 40 uM after 24 hrs by Western blot method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1375012Cytotoxicity against human Hep3B cells assessed as decrease in cell viability after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Enantiomeric neolignans from Picrasma quassioides exhibit distinctive cytotoxicity on hepatic carcinoma cells through ROS generation and apoptosis induction.
AID1355227Inhibition of p38 MAPK signaling pathway in mouse RAW264.7 cells assessed as reduction in RANKL-induced ERK phosphorylation at 10 to 40 uM after 30 mins by Western blot method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355246Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as decrease in TRAP activity at 20 uM after 5 days in presence of ERalpha antagonist MPP by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355281Anti-osteoporotic activity in Balb/c mouse assessed as inhibition of OVX-induced serum CTx level at 25 to 100 mg/kg, ip administered for 4 weeks daily by ELISA2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355220Inhibition of NF-kappaB/p38 MAPK signaling pathway in mouse RAW264.7 cells assessed as reduction in RANKL-induced NFATc1 protein expression level after 24 hrs by Western blot method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355234Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring AMPKalpha1 siRNA assessed as decrease in c-Fos mRNA level at 20 uM after 24 hrs by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355237Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as TRAP activity after 5 days in presence of estrogen receptor antagonist fulvestrant2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355232Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring AMPKalpha1 siRNA assessed as decrease in TRAP mRNA level at 20 uM after 24 hrs by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355253Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as decrease in c-Fos mRNA level at 20 uM after 24 hrs in presence of ERbeta antagonist PHTPP by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355266Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring ERbeta siRNA assessed as decrease in TRAP mRNA level at 20 uM after 24 hrs by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355247Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as decrease in c-Fos mRNA level at 20 uM after 24 hrs in presence of ERalpha antagonist MPP by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1375011Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Enantiomeric neolignans from Picrasma quassioides exhibit distinctive cytotoxicity on hepatic carcinoma cells through ROS generation and apoptosis induction.
AID1355277Anti-osteoporotic activity in Balb/c mouse assessed as decrease in OVX-induced trabecular spacing in femur at 25 to 100 mg/kg, ip administered for 4 weeks daily by microcomputed tomography2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355229Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring AMPKalpha1 siRNA assessed as decrease in number of TRAP-positive multinucleated cells after 5 days by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355279Anti-osteoporotic activity in Balb/c mouse assessed as decrease in OVX-induced structure model index in femur at 25 to 100 mg/kg, ip administered for 4 weeks daily by microcomputed tomography2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355216Inhibition of NF-kappaB/p38 MAPK signaling pathway in mouse RAW264.7 cells assessed as reduction in RANKL-induced TRAP mRNA level after 24 hrs by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355262Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring ERbeta siRNA assessed as decrease in number of TRAP-positive multinucleated cells at 20 uM after 5 days by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355267Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring ERbeta siRNA assessed as decrease in NFATc1 mRNA level at 20 uM after 24 hrs by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355257Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring ERalpha siRNA assessed as decrease in size of TRAP-positive multinucleated cells at 20 uM after 5 days by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355230Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring AMPKalpha1 siRNA assessed as decrease in size of TRAP-positive multinucleated cells after 5 days by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355226Inhibition of p38 MAPK signaling pathway in mouse RAW264.7 cells assessed as reduction in RANKL-induced JNK phosphorylation at 10 to 40 uM after 30 mins by Western blot method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355258Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring ERalpha siRNA assessed as decrease in TRAP activity at 20 uM after 5 days by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355222Inhibition of NF-kappaB/p38 MAPK signaling pathway in mouse RAW264.7 cells assessed as reduction in RANKL-induced NFATc1 nuclear translocation after 24 hrs by Western blot method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355211Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as decrease in TRAP activity at 10 to 40 uM after 5 days by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355240Induction of estrogen receptor-mediated AMPKalpha1 activation in mouse RAW264.7 cells at 20 uM in presence of CAMKKbeta inhibitor STO6092018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355268Inhibition of fluoromone binding to recombinant human full length untagged ERalpha expressed in insect cells after 2 hrs by fluorescence polarization assay2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355245Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as decrease in size of TRAP-positive multinucleated cells at 20 uM after 5 days in presence of ERalpha antagonist MPP by microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355212Inhibition of RANKL-induced bone resorption in mouse RAW264.7 cells assessed as reduction in pit formation after 7 days by optical microscopy2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355283Anti-osteoporotic activity in Balb/c mouse assessed as inhibition of OVX-induced NFATc1 mRNA expression level in bone marrow at 25 to 100 mg/kg, ip administered for 4 weeks daily by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355235Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as TRAP activity after 5 days in presence of PKA inhibitor H892018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355248Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as decrease in TRAP mRNA level at 20 uM after 24 hrs in presence of ERalpha antagonist MPP by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355221Inhibition of NF-kappaB/p38 MAPK signaling pathway in mouse RAW264.7 cells assessed as reduction in RANKL-induced c-Fos protein expression level after 24 hrs by Western blot method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355259Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells harboring ERalpha siRNA assessed as decrease in c-Fos mRNA level at 20 uM after 24 hrs by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
AID1355254Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as decrease in TRAP mRNA level at 20 uM after 24 hrs in presence of ERbeta antagonist PHTPP by qRT-PCR method2018Journal of natural products, 06-22, Volume: 81, Issue:6
Dehydrodiconiferyl Alcohol Inhibits Osteoclast Differentiation and Ovariectomy-Induced Bone Loss through Acting as an Estrogen Receptor Agonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (4.76)18.2507
2000's3 (14.29)29.6817
2010's14 (66.67)24.3611
2020's3 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.92 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index5.38 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
vanillin
Vanilla: A plant genus of the family ORCHIDACEAE that is the source of the familiar flavoring used in foods and medicines (FLAVORING AGENTS).		2.0310benzaldehydes;
monomethoxybenzene;
phenols		anti-inflammatory agent;
anticonvulsant;
antioxidant;
flavouring agent;
plant metabolite
lauric acid
dodecanoic acid : A straight-chain, twelve-carbon medium-chain saturated fatty acid with strong bactericidal properties; the main fatty acid in coconut oil and palm kernel oil.		2.0710medium-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
antibacterial agent;
plant metabolite
isoxazoles
Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.		2.3110isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
1-naphthylisothiocyanate
1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage.		2.3110isothiocyanateinsecticide
acetosyringone
acetosyringone: plant inducer which induces expression of VirE & VirG in A. tumefaciens. acetosyringone : A member of the class of acetophenones that is 1-phenylethanone substituted by a hydroxy group at position 4 and methoxy groups at positions 3 and 5.		3.0810acetophenones;
dimethoxybenzene;
phenols		anti-asthmatic drug;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug;
plant metabolite
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		2.610D-glucopyranoseepitope;
mouse metabolite
betulinic acid
[no description available]		2.1110hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
lariciresinol
lariciresinol: found in human urine. (+)-lariciresinol : A lignan that is tetrahydrofuran substituted at positions 2, 3 and 4 by 4-hydroxy-3-methoxyphenyl, hydroxymethyl and 4-hydroxy-3-methoxybenzyl groups respectively (the 2S,3R,4R-diastereomer).		2.1310aromatic ether;
lignan;
oxolanes;
phenols;
primary alcohol		antifungal agent;
plant metabolite
lignans
Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)		3.0140
gamma-sitosterol
clionasterol : A member of the class of phytosterols that is poriferast-5-ene carrying a beta-hydroxy substituent at position 3.		2.11103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
phytosterols		marine metabolite;
plant metabolite
8-hydroxypinoresinol
8-hydroxypinoresinol: cytoprotective lignan from Forsythia suspensa; structure in first source		2.1110lignan
cytellin
cytellin: a phytosterol preparation of mainly B-sitosterol, that was marketed by Eli Lilly to lower cholesterol 1957 to 1982		2.1110
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		2.1110prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
gw 4064
[no description available]		2.3110stilbenoid
(+)-dehydrodiconiferyl alcohol
(+)-dehydrodiconiferyl alcohol : A dehydrodiconiferyl alcohol that has (2S,3R)-configuration. A natural product isolated from several plant species including Allium sativum and Codonopsis pilosula.		2.1710dehydrodiconiferyl alcoholantioxidant;
plant metabolite
pinoresinol
pinoresinol: in plants; a furo[3,4-c]furan created from dimer of coniferyl alcohol. pinoresinol : A lignan that is tetrahydro-1H,3H-furo[3,4-c]furan substituted at positions 1 and 4 by 4-hydroxy-3-methoxyphenyl groups.		2.5220
cycloeucalenone
cycloeucalenone: from the stems of Tinospora crispa; structure in first source. cycloeucalenone : A pentacyclic triterpenoid that is 4alpha,14-dimethyl-9beta,19-cyclo-5alpha-ergost-24(28)-ene which is substituted by an oxo group at position 3. It has been isolated from several plant species including Quercus variabilis, Ammocharis coranica, Solanum cernuum and Tinospora crispa.		2.11103-oxo-5alpha-steroid;
cyclic terpene ketone;
pentacyclic triterpenoid		plant metabolite
balanophonin
balanophonin: from fruit wall of Cirsium vulgare; structure in first source		2.5420
ConditionIndicatedRelationship StrengthStudiesTrials
Bone Loss, Osteoclastic
[description not available]		02.1710
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Innate Inflammatory Response
[description not available]		02.2510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.2510
Bile Duct Obstruction, Intrahepatic
[description not available]		02.3110
Cholestasis, Intrahepatic
Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC).		02.3110
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		02.1110
Allergic Encephalomyelitis
[description not available]		02.1110
MS (Multiple Sclerosis)
[description not available]		02.1110
Multiple Sclerosis
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)		02.1110
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		02.0710
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		02.910